OTC: IDRSF - Idorsia Ltd

Доходность за полгода: +27.59%
Сектор: Healthcare

График акции Idorsia Ltd


О компании

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases.

Подробнее
Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing; and QUVIVIQ (daridorexant), available in 25 and 50 mg, for the treatment of adult patients with insomnia. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.

Цена ао 2.59
Выручка 0.0231
EBITDA -0.4478
Число акций ао 0.17743 млрд
P/S 33.54
P/BV 3.09
EV/EBITDA -9.62
Сайт https://www.idorsia.com
Валюта usd
Sector Health Care
Industry Biotechnology
Валюта отчета chf
Изменение цены за день: 0% (2.59)
Изменение цены за неделю: 0% (2.59)
Изменение цены за месяц: 0% (2.59)
Изменение цены за 3 месяца: +15.11% (2.25)
Изменение цены за полгода: +27.59% (2.03)
Изменение цены за год: +20.47% (2.15)
Изменение цены за 3 года: -88.64% (22.79)
Изменение цены за 5 лет: -88.31% (22.16)
Изменение цены с начала года: +17.73% (2.2)

Недооценка

Название Значение Оценка
P/S 2.3 6
P/BV -0.3623 0
P/E 0 0
EV/EBITDA -2.69 0
Итого: 4.38

Эффективность

Название Значение Оценка
ROA, % -59.58 0
ROE, % 30.75 9
Итого: 3.17

Дивиденды

Название Значение Оценка
Div yield, % 0 0
DSI 0 0
Итого: 0

Долг

Название Значение Оценка
Debt/EBITDA -2.17 10
Итого: 9.2

Импульс роста

Название Значение Оценка
Доходность Revenue, % 539.77 10
Доходность Ebitda, % 13.25 2
Доходность EPS, % -55.07 0
Итого: 3.4



Руководитель Должность Оплата Год рождения
Mr. Jean-Paul Clozel M.D. CEO & Chairman of the Board 956.86k 1955 (69 лет)
Dr. Martine Clozel Executive VP & Chief Scientific Officer N/A 1955 (69 лет)
Mr. Andrew C. Weiss Senior VP and Head of Investor Relations & Corporate Communications N/A 1968 (56 лет)
Mr. Julien Gander L.L.M. Senior VP, Group General Counsel & Company Secretary N/A 1979 (45 лет)
Mr. Alexander Khatuntsev Senior VP & Head of Global Human Resources N/A 1978 (46 лет)
Dr. Guy Braunstein M.D. Executive VP & Chief Medical Officer N/A 1956 (68 лет)
Mr. Olivier Lambert Senior VP & Head of Technical Operations N/A 1966 (58 лет)
Mr. Markus A. Riederer Senior VP & Head of Drug Discovery Biology N/A 1962 (62 года)
Mr. Alberto Gimona M.D. Executive VP & Head of Global Clinical Development N/A 1960 (64 года)
Mr. Andre C. Muller Executive VP & CFO 1963 (61 год)

Адрес: Switzerland, Allschwil, Hegenheimermattweg 91 - открыть в Google картах, открыть Яндекс картах
Сайт: https://www.idorsia.com